Intravenous Magnesium Sulphate as an Adjuvant Therapy for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Intravenous Magnesium Sulphate as an Adjuvant Therapy for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

<b>Background</b>: Intravenous magnesium sulfate (IV MgSO<sub>4</sub>) may serve as an effective adjunct therapy to improve clinical outcomes in patients experiencing acute exacerbations of chronic obstructive pulmonary disease (AECOPDs). <b>Methods</b>: A compreh...

Full description

Saved in:
Bibliographic Details
Main Authors: Taimur Farid, Abdousamad Said Omar, Sijah Varar Kandi, Soja Puthiyara Maliyekal, Tze Quan Tuen, Amrutha Thazhuthedath Vijayan, Lakshmi Sudhir Pillai, Ahmed Talaat Deiab, Muhammad Sajid, Ahmad Mesmar, Eman Ibrahim Elzain Hassan, Rijas Keethadath, Hasan Al Chalabi, Tallal Mushtaq Hashmi, Mushood Ahmed, Raheel Ahmed
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Life
Subjects:
COPD
magnesium sulfate
AECOPD
Online Access:https://www.mdpi.com/2075-1729/15/6/973
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<b>Background</b>: Intravenous magnesium sulfate (IV MgSO<sub>4</sub>) may serve as an effective adjunct therapy to improve clinical outcomes in patients experiencing acute exacerbations of chronic obstructive pulmonary disease (AECOPDs). <b>Methods</b>: A comprehensive search was conducted on PubMed, Cochrane, and EMBASE from inception to April 2025 to find eligible studies comparing IV MgSO<sub>4</sub> plus standard treatment versus standard treatment alone. A random-effects meta-analysis was conducted using RevMan. <b>Results</b>: Nine studies (seven RCTs and two observational studies) met the inclusion criteria. Pooled analysis demonstrated that adjunctive IV MgSO<sub>4</sub> significantly improved peak expiratory flow rate at 45 min (MD = 18.50, 95% CI = 6.36 to 30.65) and significantly reduced hospital admission rates from the emergency department (OR = 0.45, 95% CI = 0.23 to 0.88). No significant differences were observed in the length of hospital stay (MD = −0.83, 95% CI = −2.99 to 1.33) and adverse events (OR = 0.79, 95% CI = 0.20 to 3.13; <i>p</i> = 0.73, I<sup>2</sup> = 25%) between the two groups. <b>Conclusions</b>: Adjunct MgSO<sub>4</sub> in AECOPD is associated with significant improvement in peak expiratory flow rate at 45 min and reduced hospitalization rates. Additional large-scale, multicenter randomized controlled trials are needed to validate and strengthen these findings.
ISSN:2075-1729

Similar Items